Dr. Dunleavy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Road
Washington, DC 20037Phone+1 240-271-3902
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
- University College of Dublin National Univ SOMClass of 1994
Certifications & Licensure
- MD State Medical License 2021 - 2026
- NY State Medical License 2010 - 2026
- VA State Medical License 2024 - 2026
- DC State Medical License 2021 - 2024
Clinical Trials
- HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Roles: Contact
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 39 citationsConsensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.Augustine S. Lee, R. Hal Scofield, Katherine M. Hammitt, Nishant Gupta, Donald E. Thomas
Chest. 2021-02-01 - 10 citationsBurkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 RearrangementsRami Alsharif, Kieron Dunleavy
Hematology/oncology Clinics of North America. 2019-05-24 - 100 citationsB-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasisKieron Dunleavy, Frances T. Hakim, Hyun K. Kim, John E. Janik, Nicole Grant
Blood. 2005-08-01
Press Mentions
- DLBCL: Major New Treatment BreakthroughsMay 17th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: